Quarterly report pursuant to Section 13 or 15(d)

7. STOCKHOLDERS' EQUITY (Tables)

v3.19.1
7. STOCKHOLDERS' EQUITY (Tables)
3 Months Ended
Mar. 31, 2019
STOCKHOLDERS' EQUITY  
Schedule of assumptions
    Three Months Ended March 31,
    2019   2018
         
Expected term     5.8 - 6.3 years       6.3 years  
Volatility     61 %     57 %
Dividend yield     0.0       0.0  
Risk-free interest rate     2.25-2.63%       2.59 %
Schedule of stock option activity
    Shares   Weighted Average Exercise Price
Balance at December 31, 2018     4,342,231     $ 5.16  
Forfeited     (74,906 )   $ 4.61  
Expired     (3,740 )   $ 4.75  
Granted     1,335,850     $ 3.42  
Exercised     —       $ —    
Balance at March 31, 2019     5,599,435     $ 4.75  
                 
Options exercisable     2,588,091     $ 5.93  
Stock-based compensation expense

 

    2019   2018
         
Research and development   $ 86,523     $ 78,305  
Plasma centers     11,540       7,086  
Selling, general and administrative     498,471       394,858  
Cost of product revenue     40,729       34,535  
Total stock-based compensation expense   $ 637,263     $ 514,784